Dent, Rebecca http://orcid.org/0000-0001-6421-7602
Oliveira, Mafalda
Isakoff, Steven J.
Im, Seock-Ah
Espié, Marc
Blau, Sibel
Tan, Antoinette R.
Saura, Cristina
Wongchenko, Matthew J.
Xu, Na
Bradley, Denise
Reilly, Sarah-Jayne
Mani, Aruna
Kim, Sung-Bae
Lee, K. S.
Sohn, J. H.
Kim, J. H.
Seo, J. H.
Kim, J. S.
Park, S.
Velez, M.
Dakhil, S.
Hurvitz, S.
Valero, V.
Vidal, G.
Figlin, R.
Allison, M. A. K.
Chan, D.
Cobleigh, M.
Hansen, V.
Iannotti, N.
Lawler, W.
Salkini, M.
Seigel, L.
Romieu, G.
Debled, M.
Levy, C.
Hardy-Bessard, A.
Guiu, S.
Estevez, L. Garcia
Villanueva, R.
Martin, A. Gonzalez
Rovira, P. Sanchez
Montaño, A.
Plaza, M. I. Calvo
Saenz, J. A. García
Garau, I.
Bermejo, B.
Alonso, E. Vega
Wang, H.-C.
Huang, C.-S.
Chen, S.-C.
Chen, Y.-H.
Tseng, L.-M.
Wong, A.
Ang, C. S. P.
De Laurentiis, M.
Conte, P. F.
De Braud, F.
Montemurro, F.
Gianni, L.
Dirix, L.
,
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 9 December 2020
Accepted: 8 February 2021
First Online: 15 July 2021
Compliance with ethical standards
:
: R Dent has received honoraria from Roche, Novartis, Lilly, Pfizer, Eisai, Merck, and AstraZeneca. M Oliveira has received honoraria from Roche, has served in a consultancy/advisory role for Roche/Genentech, GlaxoSmithKline, and Puma, and has received travel/accommodation/expenses from Roche, Novartis, Grünenthal Group, Pierre Fabre, and GP Pharm; her institution has received research funding from AstraZeneca, Philips Healthcare, Genentech, Roche, Novartis, Immunomedics, Seattle Genetics, GSK, Boehringer Ingelheim, and Puma Biotechnology. SJ Isakoff has received honoraria from Genentech, Hengrui, Puma, Immunomedics, Myriad and OncoPep, Inc.; his institution has received research funding from Genentech, PharmaMar, AstraZeneca, and Merck. S-A Im has served in a consultancy/advisory role for AstraZeneca, Amgen, Eisai, Lilly, MedPacto, Novartis, Daiichi-Sankyo, Pfizer, and Roche; his institution has received research funding from AstraZeneca, Pfizer, and Roche. M Espié has received research funding from Roche, Novartis, and Pfizer. S Blau reports that her husband is the owner of the company All4Cure. AR Tan has served in a consultancy/advisory role for Immunomedics, Celgene, Pfizer, Genentech/Roche, Novartis, AbbVie, and Eisai; her institution has received research funding from Merck, Pfizer, Tesaro, Genentech/Roche, G1 Therapeutics, and Daiichi-Sankyo. C Saura has received honoraria from AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Roche, Genomic Health, Novartis, Pfizer, Pierre Fabre, Puma, and Synthon, has served in a consultancy/advisory role for AstraZeneca, Eisai, Roche, Genomic Health, Novartis, Pfizer, Puma, Sanofi, and Synthon, and has received research funding from Genentech and AstraZeneca. MJ Wongchenko, N Xu, and A Mani are employed by Genentech/Roche and hold shares in Roche. D Bradley is employed by Roche Products Ltd, holds shares in Roche, and is named as an inventor on a Roche/Genentech patent application. S-J Reilly is employed by Roche Products Ltd and holds shares in Roche. S-B Kim has served in a consulting/advisory role for Novartis, AstraZeneca, Lilly, Enzychem Lifesciences, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, and Daiichi-Sankyo and has received research funding from Novartis, Sanofi Aventis, Kyowa Kirin Inc, and DongKook Pharma Co, Ltd.
: We obtained independent Institutional Review Board approval of the protocol and all study-related documents from each participating institution, and written informed consent from all participants. The trial was performed in accordance with the Helsinki declaration and all amendments.
: All patients provided written informed consent before undergoing any study-specific procedures.